RenovaCare (RCAR) 10-Q 14 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 01, 2017
Document And Entity Information
Entity Registrant Name	Renovacare, Inc.
Entity Central Index Key	1,016,708
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		76,145,418
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,017

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 1,149,604	$ 418,031
Prepaid expenses	11,800	31,535
Total current assets	1,161,404	449,566
Equipment, net of accumulated depreciation of $291 and $53, respectively	661	898
Intangible assets	152,854	152,854
Total assets	1,314,919	603,318
Current liabilities
Accounts payable	101,911
Accounts payable - related parties	20,000	33,290
Contract payable	100,000	150,000
Interest payable to related parties	71,185	15,220
Convertible promissory notes payable to related parties, net of discount of $302,728 and $534,519, respectively	817,272	165,481
Total current liabilities	1,110,368	363,991
Total liabilities	1,110,368	363,991
Commitments and contingencies
Stockholders' equity
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.00001 par value; 500,000,000 shares authorized, 75,225,418 and 70,069,693 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	753	702
Additional paid-in capital	13,949,028	11,290,209
Retained deficit	(13,745,230)	(11,051,584)
Total stockholders' equity	204,551	239,327
Total liabilities and stockholders' equity	$ 1,314,919	$ 603,318

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets
Accumulated depreciation	$ 291	$ 53
Current liabilities
Net of discount on related party	$ 302,728	$ 534,519
Stockholders' equity
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, Authorized	10,000,000	10,000,000
Preferred stock, shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, Authorized	500,000,000	500,000,000
Common stock, shares Issued	75,225,418	70,069,693
Common stock, shares outstanding	75,225,418	70,069,693

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Consolidated Statements Of Operations
Revenue
Operating expense
Research and development	139,819	45,381	363,785	231,013
General and administrative	434,923	223,832	1,599,338	1,347,063
Total operating expense	574,742	269,213	1,963,123	1,578,076
Loss from operations	(574,742)	(269,213)	(1,963,123)	(1,578,076)
Other income (expense)
Interest income	738	149	1,195	768
Interest expense	(20,775)	(2,819)	(56,641)	(2,819)
Accretion of debt discount	(256,667)	(30,753)	(675,077)	(30,753)
Total other income (expense)	(276,704)	(33,423)	(730,523)	(32,804)
Net loss	$ (851,446)	$ (302,636)	$ (2,693,646)	$ (1,610,880)
Basic and Diluted Loss per Common Share	$ (0.01)	$ 0	$ (0.04)	$ (0.02)
Weighted average number of common shares outstanding - basic and diluted	75,123,280	69,955,847	73,837,107	69,695,772

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (UNAUDITED) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Deficit	Total
Beginning Balance, Shares at Dec. 31, 2015	67,781,934
Beginning Balance, Amount at Dec. 31, 2015	$ 678	$ 9,197,970	$ (8,973,695)	$ 224,953
Issuance of common stock from the exercise of warrants, Shares	2,273,913
Issuance of common stock from the exercise of warrants, Amount	$ 24	1,109,977		1,110,001
Issuance of common stock from the exercise of stock options, Shares	13,846
Issuance of common stock from the exercise of stock options, Amount
Stock based compensation due to common stock purchase options		296,123		296,123
Reversal of stock based compensation due to forfeiture of stock options		(13,861)		(13,861)
Discount on convertible promissory note due to detachable warrants		340,735		340,735
Discount on convertible promissory note due to beneficial conversion feature		359,265		359,265
Net loss			(2,077,889)	(2,077,889)
Ending Balance, Shares at Dec. 31, 2016	70,069,693
Ending Balance, Amount at Dec. 31, 2016	$ 702	11,290,209	(11,051,584)	239,327
Issuance of common stock from the exercise of warrants, Shares	4,592,895
Issuance of common stock from the exercise of warrants, Amount	$ 46	344,578		344,624
Issuance of common stock from the exercise of stock options, Shares	102,580
Issuance of common stock from the exercise of stock options, Amount	$ 1	(1)
July 2017 Private Placement units issued, Shares	460,250
July 2017 Private Placement units issued, Amount	$ 4	1,122,606		1,122,610
Stock based compensation due to common stock purchase options		748,350		748,350
Discount on convertible promissory note due to detachable warrants and beneficial conversion feature		443,286		443,286
Net loss			(2,693,646)	(2,693,646)
Ending Balance, Shares at Sep. 30, 2017	75,225,418
Ending Balance, Amount at Sep. 30, 2017	$ 753	$ 13,949,028	$ (13,745,230)	$ 204,551

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (2,693,646)	$ (1,610,880)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation	237
Stock based compensation expense	748,350	287,238
Accretion of debt discount	675,077	30,753
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses	19,735	(1,737)
Increase (decrease) in accounts payable	101,911	(43,407)
Increase (decrease) in accounts payable - related parties	(13,290)	9,497
Increase (decrease) in interest payable - related parties	55,965	2,819
Increase (decrease) in contract payable	(50,000)	(84,125)
Net cash flows from operating activities	(1,155,661)	(1,409,842)
Cash flows from financing activities
Proceeds from exercise of warrants and issuance of common stock	1,467,234	1,000,000
Proceeds from the issuance of convertible promissory notes	445,000	700,000
Payments of convertible promissory notes	(25,000)
Net cash flows from financing activities	1,887,234	1,700,000
Increase in cash and cash equivalents	731,573	290,158
Cash and cash equivalents at beginning of period	418,031	397,589
Cash and cash equivalents at end of period	1,149,604	687,747
Supplemental disclosure of cash flow information:
Interest paid in cash	676
Income taxes paid in cash
Supplemental disclosure of non-cash transactions:
Discount on convertible promissory note due to detachable warrants and beneficial conversion feature	$ 443,286	$ 700,000

Basis of Presentation, Organiza

Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 1. Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share	Basis of Presentation The unaudited financial statements of RenovaCare, Inc. (the “Company”) as of September 30, 2017, and for the three and nine months ended September 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Organization RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the “ CellMist TM The CellMist TM CellMist TM SkinGun TM TM TM Going Concern The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business. The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies. Over the past year, the Company has been funded through the sale of equity securities and proceeds from convertible promissory notes. As of September 30, 2017, the Company had approximately $1,149,604 of cash. On October 16, 2017, the Company completed a private placement with a group of private investors, whereby the Company received $2,300,000 from the sale of common stock and warrants. The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities. There can be no assurance as to the availability or terms upon which such financing and capital might be available. Recent Accounting Pronouncements Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. Earnings (Loss) Per Share The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570

Assets - Intellectual Property

Assets - Intellectual Property	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 2. Assets - Intellectual Property	On July 12, 2013, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an asset purchase agreement (“APA”) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach’s rights, title and interest in the CellMist TM

Contract Payable

Contract Payable	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 3. Contract Payable	On June 9, 2014, the Company, together with its wholly owned subsidiary, RenovaCare Sciences, entered into an amended asset purchase agreement (the “Amended APA”) with Dr. Jörg Gerlach, MD, PhD, pursuant to which RenovaCare Sciences purchased all of Dr. Gerlach's rights, title and interest in the CellMist™ System. The Amended APA provided for cash payments of $300,000 as partial consideration for the purchase which are payable as follows: (a) $100,000 on December 31, 2014; (b) $50,000 on December 31, 2015; (c) $50,000 on December 31, 2016; and (d) $100,000 on December 31, 2017. At September 30, 2017, $100,000 of the amount payable to Dr. Gerlach was recorded as current liabilities in the accompanying consolidated balance sheet.

Debt

Debt	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 4. Debt	September 9, 2016, $700,000 Convertible Promissory Note On September 9, 2016, the Company entered into a loan agreement (the “ Loan Agreement KCC Note Per the Loan Agreement, the Company issued KCC a Series E Stock Purchase Warrant (the “ Series E Warrant The Loan Agreement provides KCC with registration rights for all of the shares issuable upon conversion of the Note, including conversion of the note issued for the remaining $200,000, if applicable, and exercise of the Series E Warrant, beginning on the first anniversary of the Loan Agreement. The Company calculated the debt discount related to the Note and Series E Warrant by first allocating the respective fair value of the Note and Series E Warrant based upon their relative fair values to the total Note proceeds. The fair value of the Series E Warrant issued with the Note was calculated using the Black-Scholes option pricing model and the following assumptions: exercise price - $1.25 per share; market price of common stock - $1.54 per share; estimated volatility – 92.3%; risk free interest rate - 1.23%; expected dividend rate - 0% and expected life - 5.0 years. The resulting fair value of $340,735 was allocated to the Series E Warrant. The intrinsic value of the beneficial conversion feature amounted to $359,265. The resulting $700,000 discount to the Note is being accreted over the 1.25 year term of the Note. During the three and nine months ended September 30, 2017, the Company recognized $13,051 and $38,093 of interest expense and $134,728 and $399,791 of accretion related to the debt discount. The remaining debt discount of $134,728 will be amortized over the next quarter through December 31, 2017. February 2017, $445,000 Convertible Promissory Notes Between February 23, 2017 and March 9, 2017, the Company entered into three separate loan agreements containing identical terms (the “ February 2017 Loan Agreements Sierchio Investor Holders February 2017 Notes Per the February 2017 Loan Agreement, the Company issued Sierchio, the Investor and KCC a Series F Stock Purchase Warrant (the “ Series F Warrant The February 2017 Loan Agreements provide the Holders with registration rights for all of the shares issuable upon conversion of the February 2017 Notes, including exercise of the Series F Warrants, beginning on the first anniversary of the February 2017 Loan Agreements. On July 27, 2017, the Company repaid the Investor in full, including $25,000 of note principal and $676 of accrued interest. During the three and nine months ended September 30, 2017, the Company recognized $7,724 and $18,548 of interest expense and $121,939 and $275,286 of accretion related to the debt discount. The remaining debt discount of $168,000 will be amortized over the next two quarters through March 31, 2018.

Common Stock and Warrants

Common Stock and Warrants	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 5. Common Stock and Warrants	Common Stock At June 30, 2017, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share, 75,225,418 shares of common stock outstanding and 19,338,572 shares reserved for issuance under the Company’s 2013 Long-Term Incentive Plan (the “2013 Plan”) as adopted and approved by the Company’s Board of Directors (the “Board”) on June 20, 2013 that provides for the grant of stock options to employees, directors, officers and consultants (See “Note 6. Stock Options”). During the nine months ended September 30, 2017, the Company had the following common stock related transactions: · On July 21, 2017, the Company completed a self-directed offering of 460,250 units of the Company's equity securities (the "Units") at a price of $2.44 per unit for $1,122,610 in aggregate proceeds (the “ July 2017 Private Placement Series G Warrants · On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. · March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,500,000 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock. · On February 17, 2017, Thomas Bold, the Company’s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock. · On February 10, 2017, Joseph Sierchio, a member of the Company’s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock. · On February 2, 2017, Kenneth Kirkland, a member of the Company’s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock. · On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock. During the year ended December 31, 2016, the Company had the following common stock related transactions: · issued 100,000 shares of common stock, upon the exercise of a Series D Warrant at an exercise price of $1.10 per share resulting in $110,001 of proceeds to the Company. · issued 2,173,913 shares of common stock to KCC on February 2, 2016, upon the exercise of a portion of its Series B Warrant at an exercise price of $0.46 per share resulting in $1,000,000 of proceeds to the Company. · issued 13,846 shares of common stock upon the cashless exercise of an option to purchase 20,000 shares by Joseph Sierchio, a director. Warrants The following table summarizes information about warrants outstanding at September 30, 2017 and December 31, 2016: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average September 30, December 31, Exercise Description 2017 2016 Price Expiration Series A 720,000 960,000 $ 0.35 July 12, 2019 Series B - 1,326,087 $ 0.46 November 29, 2018 Series C - 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 910,000 $ 1.10 June 5, 2020 Series E 584,416 584,416 $ 1.54 September 8, 2021 Series F 14,492 - $ 3.45 February 23, 2022 & March 9, 2022 Series G 460,250 - $ 2.68 July 21, 2022 Total 2,689,158 7,280,503 As consideration for the CellMist TM A Series B Warrant with an exercise price of $0.46 to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with the 11/29 Financing. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company’s common stock resulting in proceeds of $1,000,000. On March 1, 2017, KCC exercised, in full, on a cashless basis, the remaining 1,326,087 Series B Warrants resulting in the issuance of 1,181,194 shares of common stock. A Series C Warrant with an exercise price of $0.49, to purchase 3,500,000 shares of common stock was issued on November 29, 2013 to KCC in connection with a financing. On March 1, 2017, KCC exercised, in full, on a cashless basis, the 3,500,000 Series C Warrants resulting in the issuance of 3,092,637 shares of common stock. Series D Warrants with an exercise price of $1.10 to purchase 1,010,000 shares of common stock were issued on June 5, 2015 in connection with the sale of units pursuant to a private placement. On December 6, 2016, a Series D Warrant to purchase shares was exercised resulting in the Company receiving $110,000 of proceeds. A Series E Warrant to purchase 584,416 shares of common stock was issued on September 9, 2016 in connection with the Loan Agreement. The Series E Warrant has an exercise price of the lesser of: (i) $1.54, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. Three Series F Warrants to purchase 128,985 shares of common stock were issued between February 22, 2017 and March 9, 2017 in connection with the February 2017 Loan Agreements. The Series F Warrants have an exercise price of the lesser of: (i) $3.45, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant. The Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. The Series G Warrants to purchase 460,250 shares of common stock were issued on July 21, 2017 in connection with the sale of units pursuant to the July 2017 Private Placement. The Series G Warrants have an exercise price of $2.68, are exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis using the formula contained therein.

Stock Options

Stock Options	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 6. Stock Options	On June 20, 2013, the Company’s Board adopted the 2013 Long-Term Incentive Plan and on November 15, 2013, a stockholder owning a majority of the Company’s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company’s common stock are reserved for issuance to the Company’s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of September 30, 2017, there were 19,338,572 shares available for grant. The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. The exercise price per share of common stock for options granted under the 2013 Plan will be the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023. Stock Option Activity The following table summarizes stock option activity for the nine months ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 Grants 310,000 4.20 Exercises (150,000 ) 1.12 Outstanding at September 30, 2017 545,000 3.09 8.86 years 339,275 Exercisable at September 30, 2017 375,000 2.75 8.69 years 299,075 Available for grant at September 30, 2017 19,338,572 The fair value of each stock option is estimated at the date of grant using the Black-Scholes option pricing model. There were 310,000 stock options granted during the nine months ended September 30, 2017 with a weighted-average grant date fair value of $3.38. There were 187,500 stock options granted during the nine months ended September 30, 2016 with a weighted-average grant date fair value of $1.41. During the nine months ended September 30, 2017, there were 150,000 options exercised on a cashless basis resulting in the issuance of 102,582 shares of common stock, with an aggregate intrinsic value of $397,100. There were no stock options exercised during the nine months ended September 30, 2016. Assumptions regarding volatility, expected term, dividend yield and risk-free interest rate are required for the Black-Scholes model. The volatility assumption is based on the Company's historical experience. The risk-free interest rate is based on a U.S. treasury note with maturity similar to the option award's expected life. The expected life represents the average period of time that options granted are expected to be outstanding. The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 2017 2016 Risk-free interest rate 1.93% - 2.39% 1.23%-1.41% Expected life in years 5.5 – 10.0 5.5 Weighted Avg. Expected Volatility 98% - 106% 92% Expected dividend yield 0 0 The share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time is expensed ratably over the respective vesting periods. During the three months ended September 30, 2017 and 2016, the Company recognized $127,478 and $12,951, respectively, in share-based compensation. During the nine months ended September 30, 2017 and 2016, the Company recognized $748,350 and $287,238, respectively, in share-based compensation. Stock-based compensation has been included in the Consolidated Statement of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 10,725 $ - $ 75,515 $ - General and administrative 116,753 12,951 672,835 287,238 Total $ 127,478 $ 12,951 $ 748,350 $ 287,238 The following table summarizes information about stock options outstanding and exercisable at September 30, 2017: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 0.80 10,000 6.87 0.80 10,000 6.87 0.80 1.05 55,000 6.50 1.05 35,000 6.50 1.05 1.25 7,500 7.71 1.25 7,500 7.71 1.25 1.34 7,500 7.75 1.34 7,500 7.75 1.34 1.65 10,000 8.09 1.65 10,000 8.09 1.65 1.70 7,500 8.04 1.70 7,500 8.04 1.70 1.91 130,000 8.46 1.91 130,000 8.46 1.91 2.28 7,500 8.81 2.28 7,500 8.81 2.28 4.20 310,000 9.62 4.20 160,000 9.62 4.20 Total 545,000 8.86 $ 3.09 375,000 8.69 $ 2.75

Commitments

Commitments	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 7. Commitments	Effective March 1, 2015, the Company entered into a lease agreement (the “Lease”) in the Pittsburgh Life Sciences Greenhouse at a monthly rate of $750. The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days’ prior written notice. The Lease was renewed effective March 1, 2017 at a monthly rate of $800. On August 1, 2013, the Company and Vector Asset Management, Inc. (“Vector”) entered into a Consulting Agreement whereby Vector will assist the Company with identifying subject matter experts in the medical device and biotechnology industries and to assist the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology (collectively, the “Services”). On May 1, 2016, Vector and the Company entered into an amendment to the consulting agreement. Pursuant to the amendment, the term of the agreement terminates only upon written notice, and the monthly consulting fee, in consideration of the Services, was increased to $6,800 from $5,000. No other changes were made to the agreement. In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $39,708 and $24,000 during the three months ended September 30, 2017 and 2016, respectively, and $146,538 and $134,567 during the nine months ended September 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM See also “Note 8. Related Party Transactions.”

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 8. Related Party Transactions	As compensation for their service on the Board, Dr. Kirkland and Mr. Sierchio will receive an annual retainer of $6,000, payable in equal yearly installments in arrears and prorated for any partial years of service. Additionally, on March 15, 2016, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 50,000 shares of the Company’s common stock at an exercise price of $1.91 per share. The options became fully vested upon grant. On May 11, 2017, the Company granted to each of Dr. Kirkland and Mr. Sierchio an incentive stock option to purchase up to 75,000 shares of the Company’s common stock at an exercise price of $4.20 per share. 37,500 of the May 11 grant vested immediately with the remaining 37,500 vesting in one year on May 11, 2018. The option strike prices equal the closing price of the Company’s common stock on the day of grant. The Options may be exercised on a “cashless basis” using the formula contained therein. The law firm of Sierchio & Partners, LLP, of which Joseph Sierchio, one of the Company’s directors, was a principal, has provided counsel to the Company since August 26, 2010 and beginning in September 2016, Mr. Sierchio became a partner at Satterlee Stephens LLP (“Satterlee”). Concurrently with Mr. Sierchio’s move to Satterlee, the Company engaged wih Satterlee to provide legal counsel with Mr. Sierchio maintaining his role as the Company’s primary attorney. During the three months ended September 30, 2017 and 2016, the Company recognized $15,115 and $30,080 of fees for legal services billed by firms associated with Mr. Sierchio. During the nine months ended September 30, 2017 and 2016, the Company recognized $195,783 and $121,595 of fees for legal services billed by firms associated with Mr. Sierchio. Included in accounts payable, at September 30, 2017 and December 31, 2016, is $10,000 and $11,750, respectively, owed to Satterlee. Mr. Sierchio continues his role with the Company as a director. In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems to provide it with prototypes and related documents under various agreements. Pursuant to these engagements the Company incurred expenses of $39,708 and $24,000 during the three months ended September 30, 2017 and 2016, respectively, and $146,538 and $134,567 during the nine months ended September 30, 2017 and 2016, respectively. Dr. Gerlach, from whom the Company purchased the CellMist TM On September 25, 2014, the Company entered into a Charitable Grant Agreement with the University of Pittsburgh, pursuant to which the Company committed to provide a charitable donation to the University of Pittsburgh in the aggregate amount of $75,000. The Company paid the Grant in eight quarterly installments of $9,375, with the final payment made on July 22, 2016. Dr. Gerlach, from whom the Company purchased the CellMist TM Dr. Gerlach is entitled to payments for consulting services. During the three months ended September 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $10,000 and $9,200, respectively. During the nine months ended September 30, 2017 and 2016, the Company recognized expenses related to Dr. Gerlach services of $28,540 and $33,210, respectively. Accounts payable to Dr. Gerlach amounted to $10,000 and $18,540 at September 30, 2017 and December 31, 2016, respectively. On May 1, 2015, the Company entered into the Option Agreement with Dr. Gerlach, pursuant to which the Company obtained a one-year exclusive option to evaluate the Technology, for the purpose of determining whether the Company would like to purchase or license the Technology. Pursuant to the terms of the Option Agreement, the Company paid Dr. Gerlach a non-refundable fee of $24,000, payable in four quarterly installments of $6,000, with the first installment due on May 1, 2015. The entire $24,000 option payment was recognized as research and development expense during the period ended December 31, 2015. The final $6,000 payment was made on February 1, 2016. On September 9, 2016, the Company entered into the Loan Agreement with KCC whereby KCC agreed to loan the Company up to $900,000 at an interest rate of 7%. KCC provided the Company with an initial loan of $700,000; the remaining $200,000 may be loaned prior to December 31, 2017. The Note matures on December 31, 2017, and, beginning on the first anniversary of the Note, can be converted into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23. Per the Loan Agreement, the Company issued KCC a Series E Warrant to purchase up to 584,416 shares of the Company’s common stock at a purchase price of the lesser of: (i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant. The Series E Warrant is exercisable for a period of five years and may be exercised on a cashless basis, See “Note 4. Debt” for additional disclosure. On February 23, 2017, the Company entered into two of the February 2017 Loan Agreements with Sierchio and KCC pursuant to which Sierchio loaned the Company $25,000 and KCC loaned $395,000 at an interest rate of 7%. The February 2017 Notes mature on February 23, 2018, and, beginning on the one month anniversary, can be converted into shares of the Company’s common stock at conversion rate equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76. Per the February 2017 Loan Agreement, the Company issued Sierchio, and KCC a Series F Warrant to purchase up to 7,246 shares and 114,493 shares, respectively, of the Company’s common stock at an exercise per share equal to the lesser of: (i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant. The Series F Warrant is exercisable for a period of five years from the date of issuance and may be exercised on a cashless basis. See “Note 4. Debt” for additional disclosure. On July 21, 2017, the Company entered into the July 2017 Private Placement with KCC for the sale of 410,000 units at a price of $2.44 per unit for $1,000,400 in aggregate proceeds. Each unit consisted of one share of common stock and one Series G Warrant to purchase one (1) share of common stock at an exercise price of $2.68 per share through July 21, 2022. The warrants may be exercised on a cashless basis. On June 28, 2017, KCC exercised 114,493 Series F Warrants for $3.01 per share resulting in the issuance of 114,493 shares of common stock and proceeds of $344,624. March 1, 2017, KCC exercised 1,326,087 Series B Warrants and 3,092,637 Series C Warrants, on a cashless basis, resulting in the issuance of 4,273,831 shares of common stock. On February 17, 2017, Thomas Bold, the Company’s President, CEO and Interim Chief Financial Officer exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 34,296 shares of common stock. On February 10, 2017, Joseph Sierchio, a member of the Company’s board of directors, exercised options to purchase up to 70,000 shares, on a cashless basis, resulting in the issuance of 38,642 shares of common stock. On February 2, 2016, KCC exercised a portion of its Series B Warrant for 2,173,913 shares of the Company’s common stock at an exercise price of $0.46 per share resulting in proceeds of $1,000,000. On February 2, 2017, Kenneth Kirkland, a member of the Company’s board of directors, exercised options to purchase up to 40,000 shares, on a cashless basis, resulting in the issuance of 29,642 shares of common stock. On January 10, 2017, Dr. Gerlach exercised a Series A Warrant to purchase up to 240,000 shares, on a cashless basis, resulting in the issuance of 204,571 shares of common stock.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Note 9. Subsequent Events	Management has reviewed material events subsequent of the period ended September 30, 2017 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”. On October 16, 2017, the Company completed a self-directed offering of 920,000 shares of the Company common stock at a price of $2.50 per share for $2,300,000 in aggregate proceeds. Additionally, each purchaser received one stock purchase warrant for each share of stock purchased for no additional consideration. Each warrant is exercisable at a price of $2.75 per share for a period of five years. The warrants may be exercised on a cashless basis.

Basis of Presentation, Organi16

Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Policies)	9 Months Ended
	Sep. 30, 2017
Basis Of Presentation Organization Going Concern Recent Accounting Pronouncements And Earnings Loss Per Share Policies
Basis of Presentation	The unaudited financial statements of RenovaCare, Inc. (the “Company”) as of September 30, 2017, and for the three and nine months ended September 30, 2017 and 2016, have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial reporting and include the Company’s wholly-owned subsidiary, RenovaCare Sciences. Accordingly, they do not include all of the disclosures required by accounting principles generally accepted in the United States for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, as filed with the Securities and Exchange Commission as part of the Company’s Form 10-K. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the interim financial information have been included. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.
Organization	RenovaCare, Inc., together with its wholly owned subsidiary, focuses on the acquisition, research, development and, if warranted, commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., completed the acquisition of its flagship technologies (collectively, the “ CellMist TM The CellMist TM CellMist TM SkinGun TM TM TM
Going Concern	The Company's activities have consisted principally of performing research and development activities and raising capital. These activities are subject to significant risks and uncertainties, including possible failure of preclinical testing and failing to secure additional funding before achieving sustainable revenue and profit from operations. The Company's ability to fund the development of its cellular therapies will depend on the amount and timing of cash receipts from future financing activities. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which contemplates continuation of the Company as a going concern, which is dependent upon the Company’s ability to establish itself as a profitable business. The Company does not have any commercialized products, has not generated any revenue since inception and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies. Over the past year, the Company has been funded through the sale of equity securities and proceeds from convertible promissory notes. As of September 30, 2017, the Company had approximately $1,149,604 of cash. On October 16, 2017, the Company completed a private placement with a group of private investors, whereby the Company received $2,300,000 from the sale of common stock and warrants. The Company believes that, as a result, it currently has sufficient cash to meet its funding requirements over the next year. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it will need to raise additional capital to accomplish its business plan. The Company expects to seek to obtain additional funding through the sale of its securities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.
Recent Accounting Pronouncements	Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting (Topic 718)”, which is intended to simplify several aspects of the accounting for share-based payment award transactions. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”, which supersedes ASC Topic 840, Leases, and creates a new topic, ASC Topic 842, Leases. ASU 2016-02 requires lessees to recognize a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months on its balance sheet. ASU 2016-02 also expands the required quantitative and qualitative disclosures surrounding leases. ASU 2016-02 is effective for the Company beginning January 1, 2019. Early adoption is permitted. The Company has determined that the adoption of ASU 2016-02 will currently have no impact on its consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. The guidance was effective for annual periods beginning after December 31, 2016, with early adoption permitted. The Company adopted the guidance with no material impact on its consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”, to clarify the principles used to recognize revenue for all entities. In March 2016, the FASB issued ASU 2016-08 to further clarify the implementation guidance on principal versus agent considerations. The guidance is effective for annual and interim periods beginning after December 15, 2017, and early adoption is permitted. The Company has determined that the adoption of ASU 2014-09 will currently have no impact on its consolidated financial statements. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.
Earnings (Loss) Per Share	The Company presents both basic and diluted earnings per share (“EPS”) amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570

Basis of Presentation, Organi17

Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Basis Of Presentation Organization Going Concern Recent Accounting Pronouncements And Earnings Loss Per Share Tables
Summary of computation of basic and diluted net loss per share	Following is the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2017 and 2016: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Basic and Diluted EPS Computation Numerator: Loss available to common stockholders' $ (851,446 ) $ (302,636 ) $ (2,693,646 ) $ (1,610,880 ) Denominator: Weighted average number of common shares outstanding 75,123,280 69,955,847 73,837,107 69,695,772 Basic and diluted EPS $ (0.01 ) $ (0.00 ) $ (0.04 ) $ (0.02 ) The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented: Stock options 545,000 445,000 545,000 445,000 Warrants 2,689,158 7,380,503 2,689,158 7,380,503 Convertible debt 647,813 623,067 647,813 623,067 Total shares not included in the computation of diluted losses per share 3,881,971 8,448,570 3,881,971 8,448,570

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	9 Months Ended
	Sep. 30, 2017
Common Stock And Warrants Tables
Summary of warrants outstanding	The following table summarizes information about warrants outstanding at September 30, 2017 and December 31, 2016: Shares of Common Stock Issuable from Warrants Outstanding as of Weighted Average September 30, December 31, Exercise Description 2017 2016 Price Expiration Series A 720,000 960,000 $ 0.35 July 12, 2019 Series B - 1,326,087 $ 0.46 November 29, 2018 Series C - 3,500,000 $ 0.49 November 29, 2018 Series D 910,000 910,000 $ 1.10 June 5, 2020 Series E 584,416 584,416 $ 1.54 September 8, 2021 Series F 14,492 - $ 3.45 February 23, 2022 & March 9, 2022 Series G 460,250 - $ 2.68 July 21, 2022 Total 2,689,158 7,280,503

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	Sep. 30, 2017
Stock Options Tables
Summary of stock option activity	The following table summarizes stock option activity for the nine months ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Weighted Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 257,500 1.07 Grants 187,500 1.92 Forfeitures (40,000 ) 1.65 Exercises (20,000 ) 0.80 Outstanding at December 31, 2016 385,000 1.42 Grants 310,000 4.20 Exercises (150,000 ) 1.12 Outstanding at September 30, 2017 545,000 3.09 8.86 years 339,275 Exercisable at September 30, 2017 375,000 2.75 8.69 years 299,075 Available for grant at September 30, 2017 19,338,572
Summary of assumption of stock option activity	The assumptions for volatility, expected life, dividend yield and risk-free interest rate for options granted are presented in the table below: 2017 2016 Risk-free interest rate 1.93% - 2.39% 1.23%-1.41% Expected life in years 5.5 – 10.0 5.5 Weighted Avg. Expected Volatility 98% - 106% 92% Expected dividend yield 0 0
Stock-based compensation included in consolidated statement of operations	Stock-based compensation has been included in the Consolidated Statement of Operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Research and development $ 10,725 $ - $ 75,515 $ - General and administrative 116,753 12,951 672,835 287,238 Total $ 127,478 $ 12,951 $ 748,350 $ 287,238
Summary of stock options outstanding and exercisable	The following table summarizes information about stock options outstanding and exercisable at September 30, 2017: Stock Options Outstanding Stock Options Exercisable Range of Exercise Prices Number of Shares Subject to Outstanding Options Weighted Average Contractual Life (years) Weighted Average Exercise Price Number of Shares Subject To Options Exercise Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 0.80 10,000 6.87 0.80 10,000 6.87 0.80 1.05 55,000 6.50 1.05 35,000 6.50 1.05 1.25 7,500 7.71 1.25 7,500 7.71 1.25 1.34 7,500 7.75 1.34 7,500 7.75 1.34 1.65 10,000 8.09 1.65 10,000 8.09 1.65 1.70 7,500 8.04 1.70 7,500 8.04 1.70 1.91 130,000 8.46 1.91 130,000 8.46 1.91 2.28 7,500 8.81 2.28 7,500 8.81 2.28 4.20 310,000 9.62 4.20 160,000 9.62 4.20 Total 545,000 8.86 $ 3.09 375,000 8.69 $ 2.75

Basis of Presentation, Organi20

Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Details ) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Basic and Diluted EPS Computation
Loss available to common stockholders'	$ (851,446)	$ (302,636)	$ (2,693,646)	$ (1,610,880)	$ (2,077,889)
Denominator:
Weighted average number of common shares outstanding	75,123,280	69,955,847	73,837,107	69,695,772
Basic and diluted EPS	$ (0.01)	$ 0	$ (0.04)	$ (0.02)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	3,881,971	8,448,570	3,881,971	8,448,570
Stock options [Member]
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	545,000	445,000	545,000	445,000
Warrant [Member]
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	2,689,158	7,380,503	2,689,158	7,380,503
Convertible debt [Member]
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	647,813	623,067	647,813	623,067

Basis of Presentation, Organi21

Basis of Presentation, Organization, Going Concern, Recent Accounting Pronouncements and Earnings (Loss) Per Share (Narrative) - USD ($)	1 Months Ended
	Oct. 16, 2017	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Cash and cash equivalents		$ 1,149,604	$ 418,031	$ 687,747	$ 397,589
Private Placement Member
Proceeds from sale of common stock and warrants	2,300,000

Assets _ Intellectual Property

Assets – Intellectual Property (Details Narrative) - USD ($)	1 Months Ended
	Jul. 31, 2013	Sep. 30, 2017	Dec. 31, 2016
Intangible Assets		$ 152,854	$ 152,854
Asset purchase agreement [Member] | Dr. Gerlach [Member]
Acquisition related costs	$ 52,852
Closing cash payment	$ 100,002

Contract Payable (Details Narra

Contract Payable (Details Narrative) - USD ($)	Jun. 09, 2014	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Amended APA provided for cash payments	$ 300,000
Purchase payable amount				$ 50,000	$ 50,000	$ 100,000
Contract and contribution payable			$ 100,000	$ 150,000
Subsequent Event [Member]
Purchase payable amount		$ 100,000
Dr. Gerlach [Member]
Contract and contribution payable			$ 100,000

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)	Sep. 09, 2016	Jul. 27, 2017	Feb. 28, 2017	Feb. 23, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Interest expense					$ 20,775	$ 2,819	$ 56,641	$ 2,819
Accretion of debt discount					$ (256,667)	$ (30,753)	$ (675,077)	$ (30,753)
Common stock shares reserved under stock option plan					102,582		102,582
Estimated volatility									92.00%
February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Interest expense					$ 7,724		$ 18,548
Accretion of debt discount					121,939		$ 275,286
Debt discount					168,000
Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Debt instrument terms of conversion feature							(i) $3.45, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant
KCC [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Convertible debt financing, Maximum amount					$ 395,000		$ 395,000
Interest rate					7.00%		7.00%
KCC [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Common stock shares reserved under stock option plan					114,493		114,493
KCC [Member] | Loan agreement [Member]
Interest expense					$ 13,051		$ 38,093
Accretion of debt discount					134,728		399,791
Convertible debt financing, Maximum amount	$ 900,000
Interest rate	7.00%			7.00%
Maturity date	Dec. 31, 2017			Feb. 23, 2018
Convertible debt financing, Loan received	$ 700,000			$ 395,000
Convertible debt financing, Remaining amount	$ 200,000
Debt instrument terms of conversion feature	(i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.			(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.
Exercise Price	$ 1.25
Market price of common stock	$ 1.54
Estimated volatility	92.30%
Risk free interest rate	1.23%
Expected dividend rate	0.00%
Expected life	5 years
Fair value	$ 340,735
Beneficial conversion intrinsic value	359,265
Debt discount	$ 700,000						134,728
Period for accretion of discount	1.25 years
KCC [Member] | Loan agreement [Member] | Series E Warrant [Member]
Common stock shares reserved under stock option plan	584,416
Debt instrument terms of conversion feature	(i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant.
KCC [Member] | Loan agreement [Member] | Series F Warrant [Member]
Common stock shares reserved under stock option plan			114,493
Debt instrument terms of conversion feature			(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.
Joseph Sierchio [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Convertible debt financing, Maximum amount					$ 25,000		$ 25,000
Interest rate					7.00%		7.00%
Maturity date							Feb. 23, 2018
Debt instrument terms of conversion feature							(i) $3.45, the closing price of the Company’s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76
Joseph Sierchio [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Common stock shares reserved under stock option plan					7,246		7,246
Joseph Sierchio [Member] | Loan agreement [Member]
Interest rate				7.00%
Maturity date				Feb. 23, 2018
Convertible debt financing, Loan received				$ 25,000
Debt instrument terms of conversion feature				(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.
Joseph Sierchio [Member] | Loan agreement [Member] | Series F Warrant [Member]
Common stock shares reserved under stock option plan			7,246
Debt instrument terms of conversion feature			(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.
Investor [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Convertible debt financing, Maximum amount					$ 25,000		$ 25,000
Interest rate					7.00%		7.00%
Payments of notes payable		$ 25,000
Payments of accrued interest		$ 676
Investor [Member] | Series F Warrant [Member] | February 2017 Loan Agreements [Member] | From February 23, 2017 to March 9, 2017 [Member]
Common stock shares reserved under stock option plan					7,246		7,246
Debt instrument terms of conversion feature							(i) $3.45, the closing price of the Company’s common stock on the day prior to issuance of the Series F Warrant; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant

Common Stock and Warrants (Deta

Common Stock and Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016	Feb. 02, 2016	Nov. 29, 2013
Series A [Member]
Shares of Common Stock Issuable from Warrants Outstanding	720,000	960,000
Weighted Average Exercise Price	$ 0.35
Expiration	Jul. 12, 2019
Series B [Member]
Shares of Common Stock Issuable from Warrants Outstanding		1,326,087
Weighted Average Exercise Price	$ 0.46		$ 0.46	$ 0.46
Expiration	Nov. 29, 2018
Series C [Member]
Shares of Common Stock Issuable from Warrants Outstanding		3,500,000
Weighted Average Exercise Price	$ 0.49			$ 0.49
Expiration	Nov. 29, 2018
Series D [Member]
Shares of Common Stock Issuable from Warrants Outstanding	910,000	910,000
Weighted Average Exercise Price	$ 1.10	$ 1.10
Expiration	Jun. 5, 2020
Series E [Member]
Shares of Common Stock Issuable from Warrants Outstanding	584,416	584,416
Weighted Average Exercise Price	$ 1.54
Expiration	Sep. 8, 2021
Series F Warrant [Member]
Shares of Common Stock Issuable from Warrants Outstanding	14,492
Weighted Average Exercise Price	$ 3.45
Expiration	Feb. 23, 2022
Series G [Member]
Shares of Common Stock Issuable from Warrants Outstanding	460,250
Weighted Average Exercise Price	$ 2.68
Expiration	Jul. 21, 2022
Warrant [Member]
Shares of Common Stock Issuable from Warrants Outstanding	2,689,158	7,280,503
Series F Warrant 1 [Member]
Expiration	Mar. 9, 2022

Common Stock and Warrants (De26

Common Stock and Warrants (Details Narrative) - USD ($)

Mar. 01, 2017

Feb. 10, 2017

Feb. 02, 2017

Jan. 10, 2017

Dec. 06, 2016

Sep. 09, 2016

Feb. 02, 2016

Aug. 05, 2015

Jul. 21, 2017

Jun. 28, 2017

Feb. 17, 2017

Sep. 30, 2017

Dec. 31, 2017

Dec. 31, 2016

Jul. 12, 2018

Jul. 12, 2017

Jul. 12, 2016

Dec. 31, 2015

Jul. 12, 2015

Jul. 12, 2014

Nov. 29, 2013

Common stock, par value

$ 0.00001

$ 0.00001

Common stock, Authorized

500,000,000

500,000,000

Common stock, shares Issued

75,225,418

70,069,693

Common stock, shares outstanding

75,225,418

70,069,693

Warrant exercised

102,582

Estimated volatility

92.00%

Thomas bold [Member] | Stock option [Member]

Warrant exercised

40,000

Issuance of common stock

34,296

Joseph Sierchio [Member] | Stock option [Member]

Warrant exercised

70,000

Issuance of common stock

38,642

Kenneth Kirkland [Member] | Stock option [Member]

Warrant exercised

40,000

Issuance of common stock

29,642

Series G [Member]

Weighted Average Exercise Price

$ 2.68

Series F [Member] | KCC [Member]

Warrant exercised

114,493

Issuance of common stock

114,493

Weighted Average Exercise Price

$ 3.01

Proceeds from issuance of common stock

$ 344,624

Series C Warrant [Member] | KCC [Member]

Warrant exercised

3,500,000

Issuance of common stock

3,092,637

Series B Warrant [Member] | KCC [Member]

Warrant exercised

1,326,087

Issuance of common stock

1,181,194

Proceeds from issuance of common stock

$ 1,000,000

Series B and C warrants [Member] | KCC [Member]

Issuance of common stock

4,273,831

Series A [Member] | Dr. Gerlach [Member]

Warrant exercised

240,000

Issuance of common stock

204,571

Series F Warrant [Member]

Weighted Average Exercise Price

3.45

Series F Warrant [Member] | KCC [Member]

Proceeds from issuance of common stock

$ 344,624

Series E [Member]

Warrant exercised

584,416

Weighted Average Exercise Price

1.54

Maturity period

5 years

Debt instrument conversion feature

(i) $1.54, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which KCC elects to exercise the Warrant.

Series D [Member]

Issuance of common stock

100,000

Weighted Average Exercise Price

1.10

$ 1.10

Proceeds from issuance of common stock

$ 110,001

Series D [Member] | On June 5, 2015 [Member]

Warrant exercised

1,010,000

Weighted Average Exercise Price

$ 1.10

Proceeds from issuance of common stock

$ 110,000

Series C [Member]

Warrant exercised

3,500,000

Weighted Average Exercise Price

0.49

$ 0.49

Series B [Member]

Warrant exercised

3,500,000

Issuance of common stock

2,173,913

Weighted Average Exercise Price

$ 0.46

0.46

$ 0.46

Proceeds from issuance of common stock

$ 1,000,000

Series A [Member]

Weighted Average Exercise Price

$ 0.35

Series A [Member] | Dr. Gerlach [Member]

Warrant exercised

240,000

1,200,000

Issuance of common stock

114,493

196,812

Weighted Average Exercise Price

$ 0.35

Warrant vest five equal installments

240,000

240,000

240,000

240,000

240,000

Joseph Sierchio [Member]

Warrant exercised

20,000

Issuance of common stock

13,846

Private Placement Member | Series G [Member]

Estimated volatility

102.23%

Market price of common stock

$ 2.92

Risk free interest rate

1.81%

Expected dividend rate

0.00%

Expected life

5 years

Private Placement Member | Common Stock [Member]

Fair value of the common stock

$ 634,782

2013 Plan [Member]

Warrant exercised

19,338,572

Self-directed offering [Member] | Private Placement Member | Series G [Member]

Maturity period

5 years

Number of equity securities offered under the plan, shares

460,250

Share price

$ 2.44

Number of equity securities offered under the plan, amount

$ 1,122,610

Exercise Price

$ 2.68

Fair value of the common stock

$ 487,828

February 2017 Loan Agreements [Member] | Joseph Sierchio [Member] | From February 23, 2017 to March 9, 2017 [Member]

Debt instrument conversion feature

(i) $3.45, the closing price of the Company’s common stock on the day prior to the issuance of the February 2017 Notes or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76

February 2017 Loan Agreements [Member] | Series F Warrant [Member] | From February 23, 2017 to March 9, 2017 [Member]

Warrant exercised

128,985

Maturity period

5 years

Warrants issued

3

Debt instrument conversion feature

(i) $3.45, the closing price of the Company’s common stock as quoted on the OTCQB on the day prior to issuance of the Warrant; or (ii) a twenty percent (20%) discount to the average closing price of the Company’s common stock as quoted on the OTCQB for the five days prior to the date on which the holder elects to exercise the Warrant

Stock Options (Details)

Stock Options (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Number of Options
Options outstanding - beginning balance	385,000	257,500	257,500
Options granted	310,000	187,500	187,500
Options forfeited			(40,000)
Options exercised	(150,000)		(20,000)
Options oustanding - ending balance	545,000		385,000
Options exercisable	375,000
Options available for grant	19,338,572
Weighted average exercise price
Options outstanding - beginning balance	$ 1.42	$ 1.07	$ 1.07
Options granted	4.20		1.92
Options forfeited			1.65
Options exercised	1.12		0.80
Options outstanding - ending balance	3.09		$ 1.42
Options exercisable	$ 2.75
Weighted average remaining contracted term
Options outstanding - ending balance	8 years 10 months 10 days
Options exercisable	8 years 8 months 9 days
Aggregate intrinsic value
Options outstanding - ending balance	$ 339,275
Options exercisable	$ 299,075

Stock Options (Details 1)

Stock Options (Details 1)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Expected life in years		5 years 6 months
Weighted Avg. Expected Volatility		92.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free interest rate	1.93%	1.23%
Expected life in years	5 years 6 months
Weighted Avg. Expected Volatility	98.00%
Maximum [Member]
Risk-free interest rate	2.39%	1.41%
Expected life in years	10 years
Weighted Avg. Expected Volatility	106.00%

Stock Options (Details 2)

Stock Options (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock Options Details 2
Research and development	$ 10,725		$ 75,515
General and administrative	116,753	12,951	672,835	287,238
Total	$ 127,478	$ 12,951	$ 748,350	$ 287,238

Stock Options (Details 3)

Stock Options (Details 3)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Number of Stock Options Outstanding | shares	545,000
Options Outstanding, Weighted Average Contractual Life (years)	8 years 10 months 10 days
Options Outstanding, Weighted Average Exercise Price	$ 3.09
Number of Stock Options Exercisable | shares	375,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	8 years 8 months 9 days
Options Exercisable, Weighted Average Exercise Price	$ 2.75
Exercise Price Range One [Member]
Range of Exercise Prices	$ 0.80
Number of Stock Options Outstanding | shares	10,000
Options Outstanding, Weighted Average Contractual Life (years)	6 years 10 months 14 days
Options Outstanding, Weighted Average Exercise Price	$ 0.80
Number of Stock Options Exercisable | shares	10,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	6 years 10 months 14 days
Options Exercisable, Weighted Average Exercise Price	$ 0.80
Exercise Price Range Two [Member]
Range of Exercise Prices	$ 1.05
Number of Stock Options Outstanding | shares	55,000
Options Outstanding, Weighted Average Contractual Life (years)	6 years 6 months
Options Outstanding, Weighted Average Exercise Price	$ 1.05
Number of Stock Options Exercisable | shares	35,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	6 years 6 months
Options Exercisable, Weighted Average Exercise Price	$ 1.05
Exercise Price Range Three [Member]
Range of Exercise Prices	$ 1.25
Number of Stock Options Outstanding | shares	7,500
Options Outstanding, Weighted Average Contractual Life (years)	7 years 8 months 16 days
Options Outstanding, Weighted Average Exercise Price	$ 1.25
Number of Stock Options Exercisable | shares	7,500
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	7 years 8 months 16 days
Options Exercisable, Weighted Average Exercise Price	$ 1.25
Exercise Price Range Four [Member]
Range of Exercise Prices	$ 1.34
Number of Stock Options Outstanding | shares	7,500
Options Outstanding, Weighted Average Contractual Life (years)	7 years 9 months
Options Outstanding, Weighted Average Exercise Price	$ 1.34
Number of Stock Options Exercisable | shares	7,500
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	7 years 9 months
Options Exercisable, Weighted Average Exercise Price	$ 1.34
Exercise Price Range Five [Member]
Range of Exercise Prices	$ 1.65
Number of Stock Options Outstanding | shares	10,000
Options Outstanding, Weighted Average Contractual Life (years)	8 years 1 month 2 days
Options Outstanding, Weighted Average Exercise Price	$ 1.65
Number of Stock Options Exercisable | shares	10,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	8 years 1 month 2 days
Options Exercisable, Weighted Average Exercise Price	$ 1.65
Exercise Price Range Six [Member]
Range of Exercise Prices	$ 1.70
Number of Stock Options Outstanding | shares	7,500
Options Outstanding, Weighted Average Contractual Life (years)	8 years 15 days
Options Outstanding, Weighted Average Exercise Price	$ 1.70
Number of Stock Options Exercisable | shares	7,500
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	8 years 15 days
Options Exercisable, Weighted Average Exercise Price	$ 1.70
Exercise Price Range Seven [Member]
Range of Exercise Prices	$ 1.91
Number of Stock Options Outstanding | shares	130,000
Options Outstanding, Weighted Average Contractual Life (years)	8 years 5 months 16 days
Options Outstanding, Weighted Average Exercise Price	$ 1.91
Number of Stock Options Exercisable | shares	130,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	8 years 5 months 16 days
Options Exercisable, Weighted Average Exercise Price	$ 1.91
Exercise Price Range Eight [Member]
Range of Exercise Prices	$ 2.28
Number of Stock Options Outstanding | shares	7,500
Options Outstanding, Weighted Average Contractual Life (years)	8 years 9 months 22 days
Options Outstanding, Weighted Average Exercise Price	$ 2.28
Number of Stock Options Exercisable | shares	7,500
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	8 years 9 months 22 days
Options Exercisable, Weighted Average Exercise Price	$ 2.28
Exercise Price Range Nine [Member]
Range of Exercise Prices	$ 4.20
Number of Stock Options Outstanding | shares	310,000
Options Outstanding, Weighted Average Contractual Life (years)	9 years 7 months 13 days
Options Outstanding, Weighted Average Exercise Price	$ 4.20
Number of Stock Options Exercisable | shares	160,000
Options Exercisable, Weighted Average Remaining Contractual Life (Years)	9 years 7 months 13 days
Options Exercisable, Weighted Average Exercise Price	$ 4.20

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	May 11, 2018	Dec. 31, 2016
Common shares reserved for issuance	102,582		102,582
Available shares for granted	19,338,572		19,338,572
Options granted			310,000	187,500		187,500
Weighted-average grant date fair value			$ 3.38	$ 1.41	$ 37,500
Options excercised			150,000			20,000
Aggregate intrinsic value			$ 397,100
Stock based compensation expense	$ 127,478	$ 12,951	$ 748,350	$ 287,238
2013 Plan [Member]
Common shares reserved for issuance						20,000,000
Stock options grant description						No person may be granted in any of the Company's fiscal year, options to purchase more than 2,000,000 shares under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.
Excecise price per share limit						Not be less than 110% of the fair market value
Option granted before date						Jun. 20, 2023

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	Mar. 01, 2017	Mar. 01, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	May 01, 2016	Aug. 01, 2013
Consulting Agreement [Member]
Consulting fees in consideration of the services							$ 6,800	$ 5,000
Pittsburgh Life Sciences Greenhouse [Member]
Monthly rent	$ 800	$ 750
Lease termination description		The Company has the option to terminate the Lease on the twelve month anniversary of the commencement date, upon one hundred and twenty days’ prior written notice.
StemCell Systems [Member]
Incurred expenses			$ 39,708	$ 24,000	$ 146,538	$ 134,567

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	May 11, 2017$ / sharesshares	Mar. 01, 2017shares	Feb. 10, 2017shares	Feb. 02, 2017shares	Jan. 10, 2017shares	Sep. 09, 2016USD ($)$ / sharesshares	Mar. 15, 2016$ / sharesshares	Feb. 02, 2016USD ($)$ / sharesshares	May 01, 2015USD ($)Installment	Jul. 21, 2017USD ($)$ / sharesshares	Jun. 28, 2017USD ($)$ / sharesshares	Mar. 01, 2017shares	Feb. 28, 2017shares	Feb. 23, 2017USD ($)	Feb. 17, 2017shares	Sep. 25, 2014USD ($)Installment	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / shares	May 11, 2018$ / shares	Dec. 31, 2016USD ($)
Common stock shares reserved for future issuance | shares																	102,582		102,582
Stock option grant vested | $ / shares																			$ 3.38	$ 1.41	$ 37,500
Accounts payable																	$ 20,000		$ 20,000			$ 33,290
Research and development expense																	$ 139,819	$ 45,381	$ 363,785	$ 231,013
Exercise Price | $ / shares																	$ 3.09		$ 3.09
Charitable Grant Agreement [Member]
Donation to the University																$ 75,000
Donation periodic payment																$ 9,375
Number of installments | Installment																8
Dr. Gerlach [Member]
Compensation expense for services																	$ 10,000	9,200	$ 28,540	33,210
Accounts payable																	10,000		10,000			18,540
Joseph Sierchio [Member]
Annual retainer payable																	6,000		$ 6,000
Common stock shares reserved for future issuance | shares	75,000						50,000
Exercise price | $ / shares	$ 4.20																		$ 1.91
Legal fees																	15,115	30,080	$ 195,783	121,595
Accounts payable																	10,000		10,000			11,750
Kenneth Kirkland [Member]
Annual retainer payable																	6,000		6,000
Common stock shares reserved for future issuance | shares	75,000						50,000
Exercise price | $ / shares	$ 4.20						$ 1.91
Option agreement [Member] | Dr. Gerlach [Member]
Number of installments | Installment									4
Fees payable under agreement									$ 24,000
Due to related party periodic payment									6,000
Research and development expense									$ 24,000
Series A [Member] | Dr. Gerlach [Member]
Common stock shares reserved for future issuance | shares					240,000
Debt conversion converted instrument shares issued | shares					204,571
KCC [Member] | Loan agreement [Member]
Convertible debt financing, Maximum amount						$ 900,000
Convertible debt financing, Loan received						700,000								$ 395,000
Convertible debt financing, Remaining amount						$ 200,000
Interest rate						7.00%								7.00%
Maturity date						Dec. 31, 2017								Feb. 23, 2018
Debt instrument conversion feature						(i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to convert the Note, subject to a floor price of $1.23.								(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.
Debt instrument floor price | $ / shares						$ 1.23
KCC [Member] | Series B and C warrants [Member]
Debt conversion converted instrument shares issued | shares		4,273,831
KCC [Member] | Series C Warrant [Member]
Number of warrants exercised | shares												3,092,637
KCC [Member] | Series B Warrant [Member]
Number of warrants exercised | shares												1,326,087
Debt conversion converted instrument shares issued | shares								2,173,913
Exercise Price | $ / shares								$ 0.46
Proceeds from issuance of common stock								$ 1,000,000
KCC [Member] | Series F Warrant [Member]
Number of warrants exercised | shares											114,493
Debt conversion converted instrument shares issued | shares											114,493
Exercise Price | $ / shares											$ 3.01
Proceeds from issuance of common stock											$ 344,624
KCC [Member] | Series F Warrant [Member] | Loan agreement [Member]
Common stock shares reserved for future issuance | shares													114,493
Debt instrument conversion feature													(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.
Warrant expiration period													5 years
KCC [Member] | Series E Warrant [Member] | Loan agreement [Member]
Common stock shares reserved for future issuance | shares						584,416
Debt instrument conversion feature						(i) $1.54; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which KCC elects to exercise the Series E Warrant.
Warrant expiration period						5 years
KCC [Member] | Private Placement Member
Common stock shares reserved for future issuance | shares										410,000
Unit price per share | $ / shares										$ 2.44
Proceeds from units reserved for future issuance										$ 1,000,400
Terms of agreement										Each unit consisted of one share of common stock and one Series G Warrant to purchase one (1) share of common stock at an exercise price of $2.68 per share through July 21, 2022. The warrants may be exercised on a cashless basis
KCC [Member] | Private Placement Member | Series G [Member]
Exercise price | $ / shares										$ 2.68
Joseph Sierchio [Member] | Loan agreement [Member]
Convertible debt financing, Loan received														$ 25,000
Interest rate														7.00%
Maturity date														Feb. 23, 2018
Debt instrument conversion feature														(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder(s) elect to convert the February 2017 Note(s), subject to a floor price of $2.76.
Joseph Sierchio [Member] | Stock option [Member]
Common stock shares reserved for future issuance | shares			70,000
Debt conversion converted instrument shares issued | shares			38,642
Joseph Sierchio [Member] | Series F Warrant [Member] | Loan agreement [Member]
Common stock shares reserved for future issuance | shares													7,246
Debt instrument conversion feature													(i) $3.45; or (ii) a 20% discount to the average closing price of the Company’s common stock for the five days prior to the date on which the Holder elects to exercise their Series F Warrant.
Warrant expiration period													5 years
Thomas bold [Member] | Stock option [Member]
Common stock shares reserved for future issuance | shares															40,000
Debt conversion converted instrument shares issued | shares															34,296
Satterlee Stephens LLP [Member]
Accounts payable																						$ 11,750
StemCell Systems [Member]
Incurred expenses																	$ 39,708	$ 24,000	$ 146,538	$ 134,567
Kenneth Kirkland [Member] | Stock option [Member]
Common stock shares reserved for future issuance | shares				40,000
Debt conversion converted instrument shares issued | shares				29,642

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Self-directed offering [Member]	1 Months Ended
	Oct. 16, 2017USD ($)$ / sharesshares
Number of equity securities offered under the plan, shares | shares	920,000
Share price | $ / shares	$ 2.50
Number of equity securities offered under the plan, amount | $	$ 2,300,000
Class of warrants or rights issued, description	Each purchaser received one stock purchase warrant for each share of stock purchased for no additional consideration. Each warrant is exercisable at a price of $2.75 per share for a period of five years